Pre-made Navicixizumab benchmark antibody ( Bispecific mAb, anti-DLL4;VEGFA therapeutic antibody, Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.
| Products Name (INN Index) | Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | Navicixizumab |
| Target | DLL4,VEGFA |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | OncoMed Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Fallopian tube cancer,Ovarian cancer,Peritoneal cancer |
| Conditions Discontinued | Colorectal cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | DLL4,VEGFA |
| Package |
